국내 개발 신약의 기술개발 소요기간 분석

There are more than 30 new drugs developed by Korean companies, but empirical research on the new drugdevelopment process is insufficient. This study aimed to compare the development time for new drugs developed byKorean companies with previous studies on foreign companies. This study defined and an...

Full description

Saved in:
Bibliographic Details
Published inYaghag-hoi-ji Vol. 64; no. 4; pp. 284 - 289
Main Author 조정연(Jeong-Yeon Cho), 이상원(Sang-Won Lee)
Format Journal Article
LanguageKorean
Published The Pharmaceutical Society Of Korea 30.08.2020
대한약학회
Subjects
약학
drug development
clinical trials as topic
Drug industry
pharmaceutical research
investigational new drug application
drug approval
Online AccessGet full text
ISSN0377-9556
2383-9457
DOI10.17480/psk.2020.64.4.284

Cover

Abstract There are more than 30 new drugs developed by Korean companies, but empirical research on the new drugdevelopment process is insufficient. This study aimed to compare the development time for new drugs developed byKorean companies with previous studies on foreign companies. This study defined and analyzed each milestone of thedrug development process through a public data source for new drugs approved from 1999 to 2019. The development timebefore initial human testing was 2.8 years and the time for each clinical development phase were 1.4 year, 2.4 year and3.1 year, respectively. The result was similar with the previous studies in other countries. In addition, as in the case ofprevious research, the development time has increased in recent years. KCI Citation Count: 0
AbstractList There are more than 30 new drugs developed by Korean companies, but empirical research on the new drugdevelopment process is insufficient. This study aimed to compare the development time for new drugs developed byKorean companies with previous studies on foreign companies. This study defined and analyzed each milestone of thedrug development process through a public data source for new drugs approved from 1999 to 2019. The development timebefore initial human testing was 2.8 years and the time for each clinical development phase were 1.4 year, 2.4 year and3.1 year, respectively. The result was similar with the previous studies in other countries. In addition, as in the case ofprevious research, the development time has increased in recent years. KCI Citation Count: 0
Author 조정연(Jeong-Yeon Cho), 이상원(Sang-Won Lee)
Author_xml – sequence: 1
  fullname: 조정연(Jeong-Yeon Cho), 이상원(Sang-Won Lee)
BackLink https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002615869$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNo1j81Kw0AcxBepYK19AU-5ePCQuB___TqW4kehIEjuSzbdSolkpfHiVYoIerQg0kJfQMhBxYsvlOYhDFZPA8MwM79d1Mp97hDaJzgiEhQ-ui6yiGKKIwERRFTBFmpTpliogcsWamMmZag5FzuoWxQTi5mgUknG20hVH2_ru_egKhfrchHUj6t6_l0vX4Lqq6wfVv_2_VP9-txYVTkL1p-zerbcQ9vj5Kpw3T_toPjkOO6fhcPz00G_NwwzAc2opVw5PXJjSpxQNlWWpFZD8zpVUtpkZAWmwmnMJVFOWMsTrUAnMEoAhGIddLipzadjk6UT45PJr156k01N7yIemIYMqJZN9mCTzW699cZ6n6Uuv3FTA5hg3CALQaRgP1kIaa8
ContentType Journal Article
Copyright COPYRIGHT(C) KYOBO BOOK CENTRE ALL RIGHTS RESERVED
Copyright_xml – notice: COPYRIGHT(C) KYOBO BOOK CENTRE ALL RIGHTS RESERVED
DBID P5Y
SSSTE
ACYCR
DOI 10.17480/psk.2020.64.4.284
DatabaseName Kyobo Scholar Journals
Scholar(스콜라)
Korean Citation Index
DatabaseTitleList
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Analysis of Development Time of New Drugs Developed by Korean Domestic Companies
EISSN 2383-9457
EndPage 289
ExternalDocumentID oai_kci_go_kr_ARTI_9554297
4010027866176
GroupedDBID 123
9ZL
ALMA_UNASSIGNED_HOLDINGS
P2P
P5Y
SSSTE
ACYCR
ID FETCH-LOGICAL-k647-9b258e9def21e68bc8b1cb94480c877badb6026e905718e6bb5a9849a4da44683
ISSN 0377-9556
IngestDate Sun Mar 09 07:51:25 EDT 2025
Fri Jun 20 02:12:44 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords drug development
clinical trials as topic
Drug industry
pharmaceutical research
investigational new drug application
drug approval
Language Korean
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-k647-9b258e9def21e68bc8b1cb94480c877badb6026e905718e6bb5a9849a4da44683
Notes http://www.yakhak.org/journal/view.html?uid=3158&page=1&sort=&scale=10&all_k=&s_t=&s_a=&s_k=&s_v=64&s_n=4&spage=&pn=search&year=&vmd=Full
PageCount 6
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_9554297
kyobo_bookcenter_4010027866176
PublicationCentury 2000
PublicationDate 2020-08-30
PublicationDateYYYYMMDD 2020-08-30
PublicationDate_xml – month: 08
  year: 2020
  text: 2020-08-30
  day: 30
PublicationDecade 2020
PublicationTitle Yaghag-hoi-ji
PublicationYear 2020
Publisher The Pharmaceutical Society Of Korea
대한약학회
Publisher_xml – name: 대한약학회
– name: The Pharmaceutical Society Of Korea
SSID ssib036278735
ssj0000615188
ssib051116396
ssib044765145
ssib001106857
Score 2.131969
Snippet There are more than 30 new drugs developed by Korean companies, but empirical research on the new drugdevelopment process is insufficient. This study aimed to...
SourceID nrf
kyobo
SourceType Open Website
Publisher
StartPage 284
SubjectTerms 약학
TableOfContents 서 론(Introduction) 연구 방법 (Research Methods) 결 과(Results) 고 찰(Discussion) 결 론(Conclusion) 감사의 말씀(Acknowledgment) Conflict of Interest References
Title 국내 개발 신약의 기술개발 소요기간 분석
URI https://scholar.kyobobook.co.kr/article/detail/4010027866176
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002615869
Volume 64
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX 약 학 회 지, 2020, 64(4), , pp.284-289
journalDatabaseRights – providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources (selected full-text only)
  customDbUrl:
  eissn: 2383-9457
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssib044765145
  issn: 0377-9556
  databaseCode: M~E
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Nb9MwFLfKuHBBfIoNmCKEd-lS1sRx7GPSFo2hwSSK2E5RnKQfVGpQ1x3KgQOqEBIcQUJok_YPIPUAiAs3_po2fwTPTrqk2iQ-Lo719PwRP8v5vbwPI3TX90mLWbwFEgioTkgQ6iwwhU6JbcF2MCzfksHJ24_o5lOytWvtlkq_Cl5LB0NRCV6eGVfyP1IFGshVRsn-g2RPOgUC1EG-UIKEofwrGeOGg10LO3XccDEzsEvKirSBeU2SVAVINcxc7GzICrewW1eVOuYsZWeSUTIxxXR2BxSzmmrnYE4KzRQ3kwMDOzARxU2g_yLu3fPbHb-td-Ku_rw7F7LkdKrZ4DAyzE0OYEuKwbaiuN_W96As1zoxNrjcDdnM3XQUE3CworiYyyZPfGjxDBoo9yJe_KNhKH-6zDgzj4nb6Sz80J97sD5ulR_GAKYLh6SpTNBpcvL5iZ7mRc92Likez-l1dNmX3kgvLzr1EbGJcrt8sd-ryOlVKKmQyknTheTcoJ0q2y2gHJueQ-cNm1J5j8b2q0YOSkHrZrltGRADHJI5SCXEplbBtgsIGDBylgQxxRNVmTVPmcOyl82iv-RE752aJqhZvVEsYkBL_UGrgJaal9DFTM3RnHTPXkalXnwFrWXrPVrXmnnY3_66tqbt5BnUR1cRm377Mnv9VZtODmeTQy15d5x8_JkcfdKmPybJ2-M5-c375PMHIE0nY232fZyMj66h5v1Gs7apZ1d86D04DXQuDItFPIxaRjWiTARMVAPBCbxXwGxb-KGQV6RFHLSKKouoEJbPGeE-CX1CKDOvo6V-3I9uIC00qQhIENmBGRBhAMqy_NA3Q9PYaJkg6WW0qlbFk8qrdHyOBt6C9JbRHVgurxd0PZlyXT7bsdcbeKBYPvBg1QG52St_6uUmupBv6VtoaTg4iG4DbB2KVbUrfgNLin_p
linkProvider ISSN International Centre
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%EA%B5%AD%EB%82%B4+%EA%B0%9C%EB%B0%9C+%EC%8B%A0%EC%95%BD%EC%9D%98+%EA%B8%B0%EC%88%A0%EA%B0%9C%EB%B0%9C+%EC%86%8C%EC%9A%94%EA%B8%B0%EA%B0%84+%EB%B6%84%EC%84%9D&rft.jtitle=Yaghag-hoi-ji&rft.au=%EC%A1%B0%EC%A0%95%EC%97%B0%28Jeong-Yeon+Cho%29%2C+%EC%9D%B4%EC%83%81%EC%9B%90%28Sang-Won+Lee%29&rft.date=2020-08-30&rft.pub=The+Pharmaceutical+Society+Of+Korea&rft.issn=0377-9556&rft.volume=64&rft.issue=4&rft.spage=284&rft.epage=289&rft_id=info:doi/10.17480%2Fpsk.2020.64.4.284&rft.externalDocID=4010027866176
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0377-9556&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0377-9556&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0377-9556&client=summon